Zirabev 100 mg, 25 mg, 4 ml Infusion, 1 Vial

Zirabev contains bevacizumab, a humanized monoclonal antibody used in cancer treatment.
Works by binding to VEGF, helping block the formation of blood vessels that supply tumors.
Used in the treatment of several advanced and metastatic cancers.
Administered in combination with chemotherapy or targeted therapy depending on the cancer type.

Uses:
Colorectal cancer
Non-small cell lung cancer
Glioblastoma
Kidney cancer
Ovarian cancer
Cervical cancer

Dosage and Administration:
Administered by intravenous infusion only
Given by healthcare professionals in oncology settings
Dose depends on body weight and cancer type
Usually administered every 2–3 weeks

Warnings and Precautions:
May increase risk of high blood pressure, bleeding, blood clots, and poor wound healing
Use caution in patients with recent surgery or gastrointestinal ulcers
Monitor for protein in urine and severe infections
Not to be used during pregnancy or breastfeeding

Contraindications:
Allergy to bevacizumab or recombinant antibodies
Pregnancy

Possible Side Effects:
High blood pressure
Bleeding
Diarrhea
Fatigue
Abdominal pain
Blood clots

Storage Instructions:
Store in a refrigerator (2–8°C)
Do not freeze
Keep in outer carton to protect from light